Humanigen

company

About

Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.

  • 11 - 50

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$80M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$163M
Humanigen has raised a total of $163M in funding over 2 rounds. Their latest funding was raised on Mar 10, 2021 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 10, 2021 Post-IPO Debt $80M 1 Hercules Capital Detail
Jul 1, 2016 Post-IPO Equity $11M 1 Detail
Dec 22, 2008 Series D $12M 1 Detail
Sep 23, 2008 Series D $20M 2 Detail
Aug 3, 2007 Series C $20M 1 Singapore Bio-Innovations Detail

Investors

Number of Lead Investors
Number of Investors
2
4
Humanigen is funded by 4 investors. Hercules Capital and Nomis Bay are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
Nomis Bay Post-IPO Equity
Singapore Bio-Innovations Series D
Lotus BioScience Ventures Series D